334 related articles for article (PubMed ID: 31740782)
1. The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma.
Thomsen MK; Skouboe MK; Boularan C; Vernejoul F; Lioux T; Leknes SL; Berthelsen MF; Riedel M; Cai H; Joseph JV; Perouzel E; Tiraby M; Vendelbo MH; Paludan SR
Oncogene; 2020 Feb; 39(8):1652-1664. PubMed ID: 31740782
[TBL] [Abstract][Full Text] [Related]
2. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma.
Qi Z; Yan F; Chen D; Xing W; Li Q; Zeng W; Bi B; Xie J
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33006365
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract][Full Text] [Related]
4. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
5. RECQL4 Inhibits Radiation-Induced Tumor Immune Awakening via Suppressing the cGAS-STING Pathway in Hepatocellular Carcinoma.
Hong W; Zhang Y; Wang S; Li Z; Zheng D; Hsu S; Zhou J; Fan J; Chen Z; Xia X; Zeng Z; Gao Q; Yu M; Du S
Adv Sci (Weinh); 2024 Apr; 11(16):e2308009. PubMed ID: 38381090
[TBL] [Abstract][Full Text] [Related]
6. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
7. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract][Full Text] [Related]
8. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
Ma H; Kang Z; Foo TK; Shen Z; Xia B
Hepatology; 2023 Jan; 77(1):33-47. PubMed ID: 35006619
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis.
Zhao F; Liu A; Gong X; Chen H; Wei J; Chen B; Chen S; Yang R; Fan Y; Mao R
Tumori; 2022 Feb; 108(1):63-76. PubMed ID: 34165025
[TBL] [Abstract][Full Text] [Related]
10. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity.
Wang X; Hu R; Song Z; Zhao H; Pan Z; Feng Y; Yu Y; Han Q; Zhang J
Cancer Lett; 2022 Oct; 547():215880. PubMed ID: 35981569
[TBL] [Abstract][Full Text] [Related]
12. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Activation of Immunogenic Cell Death and cGAS-STING Pathway by Liver- and Mitochondria-Targeted Gold(I) Complexes for Chemoimmunotherapy of Hepatocellular Carcinoma.
Li F; Wen Z; Wu C; Yang Z; Wang Z; Diao W; Chen D; Xu Z; Lu Y; Liu W
J Med Chem; 2024 Feb; 67(3):1982-2003. PubMed ID: 38261008
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
[TBL] [Abstract][Full Text] [Related]
15. Radiofrequency hyperthermia enhances the effect of OK-432 for Hepatocellular carcinoma by activating of TLR4-cGAS-STING pathway.
Sun B; Zhang Q; Sun T; Liu J; Cao Y; Liang B; Zheng C; Kan X
Int Immunopharmacol; 2024 Mar; 130():111769. PubMed ID: 38442584
[TBL] [Abstract][Full Text] [Related]
16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
17. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
[TBL] [Abstract][Full Text] [Related]
18. The anti-hepatocellular carcinoma effect of Brucea javanica oil in ascitic tumor-bearing mice: The detection of brusatol and its role.
Wang T; Dou Y; Lin G; Li Q; Nie J; Chen B; Xie J; Su Z; Zeng H; Chen J; Xie Y
Biomed Pharmacother; 2021 Feb; 134():111122. PubMed ID: 33341052
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
